Calcium-channel blockers and systemic hypertension.

Calcium-channel blockers selectively inhibit transmembrane flux of calcium in excitable tissues. Their ability to block calcium-mediated electromechanical coupling in contractile tissue produces peripheral vasodilation and has led to interest in their use for systemic hypertension. A postulated involvement of calcium in the development of the increased vascular tone of hypertension makes these agents appear particularly attractive for use as vasodilators. Clinical trials suggest a potentially important role for the calcium-channel blockers in the treatment of systemic hypertension.